Vitamin K2 for Heart Health: Observational vs Trial Data

Vitamin K2 (menaquinone) is built and works differently from the better-known vitamin K1 (phylloquinone) in leafy greens. K2 comes mainly from fermented foods such as Japanese natto, certain aged cheeses, and some animal liver and egg yolk; gut bacteria also make small amounts. Over the past fifteen years K2 has grown into a supplement category in its own right, driven by a clean mechanistic story about vascular calcification — and a randomized-trial track record that has been slower to arrive.

The Mechanistic Story

K2 is a cofactor for an enzyme that activates matrix Gla protein (MGP), one of the most potent known natural inhibitors of vascular calcification. When MGP stays inactive ("uncarboxylated"), calcium is more likely to deposit in artery walls, hardening the plaque that builds up in atherosclerosis — a process linked to cardiovascular events even after accounting for cholesterol. K2 also activates other vitamin K-dependent proteins, including osteocalcin (which helps direct calcium into bone). The biological logic in shorthand: K2 helps keep calcium out of arteries and into bones at the same time.

Observational Evidence: Strong but Confounded

The Rotterdam Study — a Dutch prospective cohort of 4,807 adults followed from 1990–2000 (Geleijnse et al., 2004) — found that the highest tertile of dietary menaquinone intake was associated with a 57% lower risk of coronary heart disease mortality compared with the lowest tertile (relative risk 0.43, 95% CI 0.24–0.77), and with significantly less severe aortic calcification. The Dutch Prospect-EPIC cohort (Gast et al., 2009) reported similar results: higher dietary K2 was linked to a lower incidence of coronary heart disease in postmenopausal women. These are among the stronger diet-outcome associations in cardiovascular epidemiology. The catch: most K2 in the diet comes from fermented foods (natto, aged cheeses) and organ meats — eating patterns that often travel with other lifestyle factors, leaving room for residual confounding.

Randomized Trial Evidence: Promising but Incomplete

Several RCTs have tested K2 against surrogate (intermediate) cardiovascular markers rather than heart attacks or deaths. Daily MK-7 (the long-chain form, menaquinone-7) at 180–360 mcg consistently reduces circulating inactive MGP, confirming biological activity. The clearest cardiovascular surrogate trial is Knapen et al. (2015), in which 244 healthy postmenopausal women took 180 mcg/day MenaQ7 (MK-7) or placebo for three years; the supplement group showed significantly less worsening of carotid-femoral pulse wave velocity and Stiffness Index β — measures of arterial stiffness — particularly in women whose arteries were already stiffer at baseline. Smaller Dutch and German trials have hinted at slowed progression of coronary artery calcification, with mixed results. What is still missing: adequately powered, multi-year trials measuring hard endpoints — heart attacks, strokes, cardiovascular death — that would justify treating K2 like a proven cardiovascular drug.

The verdict: K2 has a plausible mechanism and respectable observational support. The randomized-trial evidence is encouraging on intermediate markers, but not yet definitive for the outcomes patients actually care about. For adults concerned about vascular calcification, or those taking calcium supplements (which may modestly raise calcification risk), 100–200 mcg/day of MK-7 is a low-risk, potentially high-upside addition while better trial data accumulate. K2 has known interactions with vitamin K antagonist anticoagulants (warfarin), so anyone on those drugs should not start a K2 supplement without their prescriber's sign-off.